Effect of streptozotocin-induced diabetes on somatostatin receptors in the anterior pituitary, hypothalamus and cerebral cortex of the male rat.
In order to better understand the mechanisms underlying the reduction in GH secretion in diabetic rats, we have characterized and measured SRIH receptors in the hypothalamus and anterior pituitary gland 5 and 9 days after induction of diabetes in the rat. Experimental diabetes was induced by an intraperitoneal injection of streptozotocin (STZ) at a dose of 65 mg/kg. Basal plasma GH was significantly reduced in diabetic rats. Chronic insulin replacement therapy partly restored plasma GH and blood glucose levels in these animals. A significant reduction in SRIH receptor concentrations was demonstrated in the hypothalamus and anterior pituitary gland, 5- and 9- days after STZ injection. These changes were not significantly corrected by insulin replacement. Cerebral cortex SRIH receptor concentrations were unaffected by experimental diabetes. We conclude that hypothalamic and pituitary SRIH receptor levels are lowered in diabetic rats. These changes may contribute to aberrant GH secretion in diabetes and they indicate that pituitary sensitivity to exogenous somatostatin should be tested in diabetic patients.
Pesce
G
G
Laboratoire de Neuroendocrinologie Expérimentale, INSERM U 297, Institut Fédératif Jean Roche, Faculté de Médecine Nord, Marseille, France.
Guillaume
V
V
Dutour
A
A
Dadoun
F
F
Joanny
P
P
Steinberg
J
J
Oliver
C
C
D000818:Animals; D002540:Cerebral Cortex / Q000737:chemistry*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D013006:Growth Hormone / Q000097:blood; D007031:Hypothalamus / Q000737:chemistry*; D008297:Male; D010903:Pituitary Gland, Anterior / Q000737:chemistry*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017481:Receptors, Somatostatin / Q000032:analysis*
D017481:Receptors, Somatostatin; D013006:Growth Hormone